Aibotics Inc. (AIBT)
| Market Cap | 2.21M +105.9% |
| Revenue (ttm) | n/a |
| Net Income | -2.09M |
| EPS | -0.00 |
| Shares Out | 850.17M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,634,724 |
| Open | 0.0021 |
| Previous Close | 0.0022 |
| Day's Range | 0.0021 - 0.0028 |
| 52-Week Range | 0.0003 - 0.0169 |
| Beta | 0.73 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About Aibotics
Aibotics Inc., together with its subsidiaries, engages in the study of psychedelics for the treatment of mental health issues in the United States. It provides psychedelic-enhanced holistic methodologies for the treatment of palliative care, depression, and anxiety. The company was formerly known as Mycotopia Therapies, Inc. and changed its name to Aibotics Inc. in February 2025. Aibotics Inc. is based in Miami, Florida. [Read more]
Financial Performance
Financial StatementsNews
AIBotics Advances PHILL ROBOT™ Trademark Protection as AI Wellness Platform Moves Toward Commercialization
Waterstone Edge handling final extension of U.S. trademark application as AIBotics continues development of its proprietary AI-powered wellness robot Waterstone Edge handling final extension of U.S. t...
Mycotopia Therapies Inc. Announces Name Change to AIBiotics, Inc. and Symbol Change to AIBT
MIAMI, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc. dba AIBotics (“AIBotics” or the “Company”) (OTC: TPIA) and a wholly owned subsidiary of Ehave (OTC: EHVVF), a developer and manager of...
AIBotics Provides 2025 Update; Strengthens Position in AI, Wellness, and Robotics
MIAMI, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc. dba AIBotics (“AIBotics" or the "Company") (OTC: TPIA), a developer and manager of AI- and robotics-enhanced companies and technologie...
Mycotopia Therapies Acquires AI Robotics Assets with a Total Transaction Value of $9 Million
MIAMI, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc. (“Mycotopia Therapies”) (“the Company”) (OTC: TPIA) announced today it has purchased certain assets of Philon Labs, LLC ("Philon Labs"...
PSLY.com, Inc. Ei.Ventures, Inc. and Mycotopia Therapies Inc. Terminate Agreement and Plan of Merger
MIAMI and MAUI, Hawaii, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Ei.Ventures, Inc. (Ei.Ventures) and Mycotopia Therapies Inc. (“Mycotopia Therapies”)(OTC: TPIA) announced today that on February 16, 2023, PSL...
Mycotopia Therapies Inc. Update on Ei.Ventures and Strategic Investments
MIAMI, May 09, 2022 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc. (OTC Pink: TPIA), a biopharma company focused on research, technology, and the development of medical psychedelics, and Ei.Ventures Inc...
Mycotopia Therapies Partners with Public Policy Specialist PsychedelicsEUROPE to Explore Opportunities in the European Market
Driving factors for growth in the European psychedelics market include growing acceptance of psychedelic medicine for treating depression and increasing prevalence of depression and mental disorders D...
Mycotopia Therapies Inc. To Enter $13 Billion Medicinal Mushroom Market With HAVN Life Sciences' Biopharmaceuticals And Ei.Ventures MANA Products
Mycotopia Therapies and Ei.Ventures are moving forward with plans to form PSLY.COM; HAVN Life Sciences' functional mushrooms will be used in PSLY.COM's MANA products, its line of whole-plant based med...
Mycotopia Therapies, Inc. Expands Presence In The Registered Mushroom Sector With HAVN Life Sciences Inc.
Mycotopia Therapies plans to distribute HAVN's line of natural OTC health products currently being registered with the Jamaican Ministry of Health Mycotopia Therapies plans to distribute HAVN's line o...
Mycotopia and Ei.Ventures sign LOI to Explore Merger and Formation of PSLY.COM, a $360 Million Transaction, And Will Apply To List Shares On NASDAQ
Post-acquisition company would focus on Ei.Ventures' flagship product Psilly, a whole-plant Botanical Psilocybin-based formulation, which is currently in the pre-clinical phase Post-acquisition compan...
Mycotopia Therapies Announces Plan to Develop Psychedelic Sublingual Tablet to Help Treat Depression
MIAMI, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc. (OTC Pink: TPIA) (the “Company”), a biopharma company focused on research, technology, and the development of medical psychedelics, an...
Mycotopia Therapies Appoints Experienced Mental Health Professional Senator Dr. Saphire Longmore M.B.B.S., DM As Chief Medical Officer Of Caribbean Affairs
MIAMI, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc. (OTC Pink: TPIA) (the “Company”) today announced the appointment of Saphire Longmore M.B.B.S., DM, to the role of Chief Medical Office...
Psytech To Merge With Wesana; Mycotopia Shareholders Will Benefit From The Transactions
PsyTech Inc, including the psychiatric therapeutic SaaS platform Tovana Solutions and psychiatric clinical network Tovana Clinics, to become wholly owned subsidiary of Wesana Health as part of definit...
Mycotopia Therapies PsyTech Inc. Announces Third Annual Psytech Summit on July 19th and 20th, 2021
Virtual Conference boasts some of the biggest names in the psychedelic industry Virtual Conference boasts some of the biggest names in the psychedelic industry